Four grants fund evaluation of therapeutic approaches to asthma, sepsis, and arthritis.
Adenosine Therapeutics was awarded four new grants totaling approximately $1,887,634. These grants will help further evaluate new therapeutic approaches for the treatment of asthma, sepsis, and arthritis.

The NIAID funded the grants: a Phase I STTR-AT grant of $861,737 to further expand research on the use of apadenoson, the company’s selective A2A agonist that is in Phase III testing as a heart imaging agent for the treatment of sepsis; a Phase II SBIR grant totaling $755,496 to identify an A2BR antagonist as a therapeutic candidate for the treatment of asthma; a Phase I STTR grant for $132,798 to further expand its preclinical research on the use of agents that activate the adenosine A2A receptor subtypes for the treatment of S. aureus sepsis; and a Phase I STTR of $137,603 to further expand its clinical research on the use of agents that activate the adenosine A2A receptor subtypes for the treatment of arthritis.

Previous articleAstraZeneca’s Stroke Drug Trial Failure Precipitates Stock Tumble
Next articleCiphergen Stockholders Sanction Life Science Research Business Sale to Bio-Rad for $20M